Paper20162413
Unbalanced reporting of benefits and harms in abstracts on rofecoxib.
Jørgensen AW and 2 others. Eur J Clin Pharmacol, 2010. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Unbalanced reporting of benefits and harms in abstracts on rofecoxib. Papers, record 20162413. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20162413
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Inflammatory Agents, Non-Steroidal | Major topic |
| Gastrointestinal Hemorrhage | Major topic |
| Lactones | Major topic |
| Sulfones | Major topic |
| Thrombosis | Major topic |
| Clinical Trials as Topic | |
| Double-Blind Method | |
| Humans |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2702836 | Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. | Control Clin Trials | 1989 | https://conductscience.org/library/papers/2702836 | PubMed |
| 2 | 18221781 | CONSORT for reporting randomised trials in journal and conference abstracts. | Lancet | 2008 | https://conductscience.org/library/papers/18221781 | PubMed |
| 3 | 17569906 | FDA places "black box" warning on antidiabetes drugs. | BMJ | 2007 | https://conductscience.org/library/papers/17569906 | PubMed |
| 4 | 11509060 | Risk of cardiovascular events associated with selective COX-2 inhibitors. | JAMA | 2001 | https://conductscience.org/library/papers/11509060 | PubMed |
| 5 | 12775615 | Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. | BMJ | 2003 | https://conductscience.org/library/papers/12775615 | PubMed |
| 6 | 8707496 | Influences on the quality of published drug studies. | Int J Technol Assess Health Care | 1996 | https://conductscience.org/library/papers/8707496 | PubMed |
| 7 | 15917385 | Academic medical centers' standards for clinical-trial agreements with industry. | N Engl J Med | 2005 | https://conductscience.org/library/papers/15917385 | PubMed |
| 8 | 19273522 | Research Transparency. Industry attack on academics. | BMJ | 2009 | https://conductscience.org/library/papers/19273522 | PubMed |
| 9 | 12672188 | Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. | J Rheumatol | 2003 | https://conductscience.org/library/papers/12672188 | PubMed |
| 10 | 17227134 | Ghost authorship in industry-initiated randomised trials. | PLoS Med | 2007 | https://conductscience.org/library/papers/17227134 | PubMed |
| 11 | 11712924 | Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. | JAMA | 2001 | https://conductscience.org/library/papers/11712924 | PubMed |
| 12 | 9874808 | Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. | Proc Natl Acad Sci U S A | 1999 | https://conductscience.org/library/papers/9874808 | PubMed |
| 13 | 11792343 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). | Am J Cardiol | 2002 | https://conductscience.org/library/papers/11792343 | PubMed |
| 14 | 17124012 | Dangerous deception--hiding the evidence of adverse drug effects. | N Engl J Med | 2006 | https://conductscience.org/library/papers/17124012 | PubMed |
| 15 | 17235089 | What have we learnt from Vioxx? | BMJ | 2007 | https://conductscience.org/library/papers/17235089 | PubMed |
| 16 | 10514410 | Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. | Am J Pathol | 1999 | https://conductscience.org/library/papers/10514410 | PubMed |
| 17 | 16339408 | Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16339408 | PubMed |
| 18 | 7715044 | The accuracy of drug information from pharmaceutical sales representatives. | JAMA | 1995 | https://conductscience.org/library/papers/7715044 | PubMed |
| 19 | 15625342 | Rofecoxib, Merck, and the FDA. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15625342 | PubMed |
| 20 | 18413874 | Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. | JAMA | 2008 | https://conductscience.org/library/papers/18413874 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42852177 | Understanding pharmaceutical industry coalitions: a case study of Mallinckrodt. | Humanit Soc Sci Commun | 2026 | https://conductscience.org/library/papers/42852177 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20162413
GET https://conductscience.org/api/papers/v1/20162413/references?page=2